The strategic optimization of investigator databases is a pivotal factor in enhancing trial enrollment and expediting study start-ups. This optimization not only serves the dual purpose of facilitating patient access to groundbreaking therapies but also ensures that biotechnological entities remain at the forefront of innovation.
Institutional Review Boards: Accelerating oncology clinical trials
Central to this discourse is the recognition of sites utilizing central Institutional Review Boards (IRBs) over local IRBs. The efficiency of central IRBs in streamlining study start-up timelines cannot be overstated. These sites inherently possess the capability to become operational at an accelerated pace, thereby attracting a greater volume of trials. This is of paramount importance as the industry gravitates towards a more dynamic and competitive environment, where the speed of site activation directly correlates with the success and viability of clinical trials.
Precision Site Network (PSN) was purpose-built to create closer and more efficient relationships with sites. The network has been onboarding more sites with Central IRB in the US to increase the variety of these sites in the network.
Leveraging partnerships for faster study startups
The PSN exemplifies an innovative approach to leveraging historical data and pre-established confidentiality agreements to streamline the setup processes. Expediting activation of PSN sites via master CDA’s, abbreviated feasibility questionnaires, PSV, waivers, and direct document access, along with dedicated site contacts, accelerates engagement and reduces site administrative burden .
One of the unique strengths of PSN is its ability to harness the power of multidisciplinary team (MDT) meetings and scientific review committees. These platforms are instrumental in identifying potential trial candidates, especially new patients who have not yet commenced treatment. This approach is particularly beneficial for biomarker studies and trials requiring patients who have not undergone extensive prior treatments, such as chemotherapy.
Innovative patient recruitment strategies in oncology research
Additionally, PSN’s utility extends to enhancing recruitment strategies. For sites lacking an inherent patient database, PSN’s ability to complement these sites with its extensive database and employ advocacy recruitment tools becomes a game-changer. This synergy not only makes certain sites viable but also underscores the importance of creative and outside-the-box thinking in patient recruitment strategies.
Efficient study startup timelines
The operational efficiency of PSN is further highlighted through its role in meeting stringent sponsor demands, particularly concerning study startup timelines.
- In a recent instance, we helped our Sponsor meet an ambitious recruitment date by tapping into our team’s deep indication experience and our relationship with a PSN site. We then built a recruitment strategy optimized for that specific site to avoid potential delays that could impact sponsor timelines.
Clinical trial efficiency: Establishing new benchmarks with PSN
In essence, the PSN offers a holistic solution to the challenges faced by biotech companies in oncology trial enrollments. By prioritizing sites with central IRBs, utilizing historical data for expedited start-ups, and adopting innovative recruitment strategies, the network not only meets the immediate needs of sponsors but also sets a new standard in clinical trial efficiency and effectiveness. As the industry continues to evolve, the strategic optimization of investigator databases through networks like PSN will undoubtedly play a critical role in shaping the future of clinical research.
